Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy combined with bevacizumab for progressive desmoid-type fibromatosis after close observation
ChiCTR2300070397Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital & Institute
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in aggressive fibromatosis (AF), sponsored by Sichuan Cancer Hospital & Institute. Primary endpoint: Event-free survival rate at 12 months. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on ChiCTR2300070397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070397.